

5th world Congress of ISFP, Vienna, Austria


Are there any methods to improve transplantation outcomes?


S. Samuel Kim, MD, FACOG Center for Fertility and Reproduction American-Sino Women's and Children's Hospital




S. Samuel Kim

Disclosure information: Nothing to declare





Is ovarian transplantation an efficient procedure?



What do we know?

- To date, roughly 100 babies were born after autotransplantation of frozen-thawed ovarian tissue but the exact number of pregnancies and live births worldwide is unknown.
- In the literature, pregnancy rates after ovarian tissue transplantation is 20-30% in some centers.
- However, these rates may not reflect actual pregnancy rates of all centers worldwide due to the absence of reports of non-pregnancies after attempted transplantations (unknown denominator).

What do we know?

- Currently, the number of human ovarian transplantation in the literature is around 455.
- Utilization rate of cryopreserved ovarian tissue is between 3-5%.
- Difficult to assess true POF rates after cancer treatment in patients who stored ovarian tissue (it appears that approximately 70% remains ovarian function).

What do we know?

- Most of success (live births) came from Europe (82/95: according to 2017 published data).
- Higher pregnancy rates with women under 35 years old.
- To date, the slow freezing method was applied in all (but three) successful cases.
- Very little data on perinatal outcomes.


Challenging issues that can affect the outcomes of ovarian transplantation

- Patient selection criteria: age, ovarian reserve, prognosis
- Cryoinjury
- Effective graft sites & methods
- Ischemic-reperfusion injuries
- Premature follicle activation
- Quality of oocytes matured in a graft
- Safety issues: especially, cancer cell transmission

To improve the outcomes:

Do we need patient selection criteria?

Age, Ovarian reserve, Prognosis, Risk of POF



Age matters?

Higher pregnancy rates with women under 35 years old (28.6 % vs 18.2 %)

No reported pregnancy after 38 years old (age at the time of cryo).


Van der Ven et al., Hum Reprod, 2016

To improve the outcomes:

How to prepare and cryopreserve ovarian tissue







How to cryopreserve ovarian tissue?

Slow freezing vs. vitrification

Slow freezing


 Currently, slow freezing is the standard method. To date, almost all pregnancies after transplantation were from ovarian tissue cryopreserved using a slow freezing method.


70-80% of primordial follicles survive after slow freezing and thawing. Nevertheless, ultrastructural damage can be detected by TEM.


vitrification


- Improved success with vitrification has been reported (Ketros et al., Hum Reprod. 2009; 24:1670-83)
- 2 live births after in vitro activation of vitrified ovarian tissue (Suzuki et al., Hum Reprod. 2015)
- However, vitrification of ovarian tissue can induce more DNA damage (Kim SS, et al., Fertil Steril, 2010)

Effects of vitrification on follicles in ovarian tissue










Surgical <u>techniques</u> and <u>sites</u> of autotransplantation ovarian tissue


Orthotopic:


- onto the remaining ovary
- into the peritoneal pocket

Hetrotopic:

subcutaneous, intramuscular, anterior peritoneum etc.







For fertility restoration, orthotopic transplantation should be the method of choice.

There is no prospective randomized study comparing the efficacy of different surgical techniques.

To improve the outcomes:

Do we need to use angiogenic agents?

Ischemic Injury after transplantation is the most detrimental to follicles, since angiogenesis takes more than 48 hours after transplantation



How to minimize ischemic injury?

- Facilitate angiogenesis: stimulate with angiogenic factors, manipulation of VEGF gene expression
- Protect oxidative damage and apoptosis caused by hypoxia: antioxidants, anti-apoptotic agents

Angiogenic agents

Agents that may enhance angiogenesis after transplantation

- 1. Gonadotropin
- 2. VEGF, Angiopoietin
- 3. G-CSF (granulocyte colony stimulating factor)
- 4. Simvastatin, methylprednisolone
- 5. Mesenchymal stem cells
- 6. Extracellular matrix/endothelial cells

Currently, no specific agent for angiogenesis has been clinically applied for ovarian transplantation in most of centers, but it may be in the future

Summary

- Human ovarian transplantation has been very successful, but its efficacy and safety need to be improved for routine clinical applications.
- Currently, slow freezing is the standard cryopreservation method for ovarian tissue.
- Orthotopic transplantation of ovarian tissue (either onto the ovary or peritoneal pocket) is recommended for fertility restoration.
- It is crucial to minimize ischemic damage after transplantation to improve outcomes.

